Seeking Alpha

DelMar Pharma reports results for six-month period ended June 30

  • DelMar Pharmaceuticals (OTCQB:DMPI) six-month results: Revenues: $0; Operating Expenses: $2.7M (-27.5%); Net Loss: ($2.8M) (+80.3%); Loss Per Share: ($0.09) (+82.4%); Quick Assets: $4.8M (+15.1%); Cash Burn: ($1.8M) (+44.9%).
  • On July 21, 2014 the BOD voted to change the fiscal year end from December 31 to June 30. The reported financial results are for the transition period.
  • No financial guidance given.

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs